Skip to content

Prevalence and Burden of Hepatitis D Virus Infection in China Through Preoperative Examination Test (Predict Study)

Prevalence and Burden of Hepatitis D Virus Infection in China Through Preoperative Examination Test (Predict Study)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05394623
Enrollment
5000
Registered
2022-05-27
Start date
2022-11-01
Completion date
2023-07-01
Last updated
2022-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antibodies; Anti-D, Hepatitis B, Hepatitis D, RNA Virus Infections

Brief summary

In China, there is no recommendation for Hepatitis D virus (HDV) screening, but the fact is estimated that one-third of the world's population of individuals with chronic Hepatitis B virus (HBV) infection live in China while we do not know the prevalence of co-infection of HBV/HDV in China. So far, no nationwide study has been undertaken to evaluate the epidemiology of hepatitis D, on the other hand, reports of HDV infection rate in different regions of China are not consistent because of the different detection methods and detection objects. Here, we plan to test HDV-Ab/RNA for 5000 HBsAg reactive samples from 10 major tertiary hospital and to know the prevalence and disease burden of HDV in China.

Interventions

DIAGNOSTIC_TESTHDV-Ab (IgG), HDV-RNA, RNA genotype

Anti-HDV was evaluated semiquantitatively by means of end-point dilutions. Quantitative HDV-RNA was performed by means of LightCycler 2.0. Genotyping of HDV was performed by direct sequencing of the delta antigen region.

Sponsors

Gilead Sciences
CollaboratorINDUSTRY
The First Affiliated Hospital with Nanjing Medical University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Positive HBV surface antigen (HBsAg) 2. Age 18 yeas and above

Exclusion criteria

1\. Severe cardiac, renal, respiratory, hematological, or psychiatric illness.

Design outcomes

Primary

MeasureTime frameDescription
HDV seroprevalence and HDV RNA prevalence amongst HBsAg positive carriers in China.3 monthsBriefly, serum samples were tested undiluted, and after dilution of 1:10, 1:100, 1:1,000, 1:5,000, 1:10,000, 1:50,000, and was considered the highest dilution with a S/Co value \>1.0. The detection system consisted of a competitive enzyme immunoassay, in which Anti-HDV antibodies (IgG/IgM), if present in the sample, compete with a virus-specific human polyclonal IgG, labeled with peroxidase (HRP), for a ţxed amount of full-length rec-HDV coated on the microplate. Qualitative HDV RNA was determined by in-house Polymerase Chain Reaction (PCR). Quantitative HDV-RNA was performed by means of LightCycler 2.0 (lower limit of detection 10 copies/reaction).

Secondary

MeasureTime frameDescription
The distribution of HDV genotypes in China3 monthsGenotyping of HDV was performed by direct sequencing of the delta antigen region.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026